Efficacy of telbivudine on patients with chronic hepatitis B and factors of predict efficacy

Objective:To investigate the efficciency of telbivudine on patients with chronic hepatitis B and evaluate the factors of can predict the efficacy.Methods:The virology,serology and biochemical indicators of 200 patients who received telbivudine for the treatment of chronic hepatitis B were detected and analysised before and at week 12,24 and 48 of the treatment,in order to get the predict efficacy factors of the treatment.Results:After 48 weeks of treatment,HBV DNA negative rate was 85.5%,HBeAg seroconversion rate was 26.76%,ALT normalization rate was 76%,and drug resistant rate was 3.5%;HBV DNA negative rate of HBeAg-negative group was significantly higher than that of HBeAg-positive group(P﹤0.05);The rates of HBV DNA negative and HBeAg seroconversion in patients with base ALT5×ULN were significantly higher than those in patients with ALT 2～5×ULN(P﹤0.05);The rates of HBV DNA negative,ALT normalization and HBeAg seroconversion at week 48 after treatment in patients with HBV DNA negative at week 24 were significantly higher(P﹤0.05).In the course of treatment,43.5% of patients had CK elevation,but there was no case stopping treatment for severe adverse effect.Conclusion:Telbivudine can inhibit HBV DNA replication,normalize ALT and promote HBeAg seroconversion,moreover the rate of drug resistance is low.It's a safe and effective antiviral drug.